Heron Therapeutics (HRTX)
(Delayed Data from NSDQ)
$1.83 USD
-0.04 (-2.14%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $1.82 -0.01 (-0.55%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Income Statements
Fiscal Year end for Heron Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 127 | 108 | 86 | 89 | 146 |
Cost Of Goods | 65 | 55 | 46 | 36 | 62 |
Gross Profit | 62 | 53 | 40 | 52 | 84 |
Selling & Adminstrative & Depr. & Amort Expenses | 173 | 227 | 258 | 281 | 295 |
Income After Depreciation & Amortization | -111 | -175 | -218 | -228 | -211 |
Non-Operating Income | 4 | -5 | 0 | 3 | 7 |
Interest Expense | 4 | 2 | 2 | 2 | 1 |
Pretax Income | -111 | -182 | -221 | -227 | -205 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -111 | -182 | -221 | -227 | -205 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -111 | -182 | -221 | -227 | -205 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -109 | -172 | -214 | -224 | -211 |
Depreciation & Amortization (Cash Flow) | 2 | 2 | 4 | 4 | -1 |
Income After Depreciation & Amortization | -111 | -175 | -218 | -228 | -211 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 138.20 | 109.00 | 98.47 | 90.77 | 81.78 |
Diluted EPS Before Non-Recurring Items | -0.80 | -1.67 | -2.24 | -2.50 | -2.50 |
Diluted Net EPS (GAAP) | -0.80 | -1.67 | -2.24 | -2.50 | -2.50 |
Fiscal Year end for Heron Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 36.02 | 34.67 | 34.23 | 31.43 | 31.76 |
Cost Of Goods | 10.52 | 8.44 | 9.89 | 18.21 | 20.16 |
Gross Profit | 25.51 | 26.23 | 24.35 | 13.23 | 11.60 |
SG&A, R&D, and Dept/Amort Expenses | 31.95 | 31.03 | 34.57 | 38.16 | 54.01 |
Income After SG&A, R&D, and Dept/Amort Expenses | -6.44 | -4.80 | -10.22 | -24.93 | -42.41 |
Non-Operating Income | -2.79 | 1.64 | 3.36 | -0.08 | 0.34 |
Interest Expense | 0.00 | 0.00 | 3.87 | 0.00 | 0.00 |
Pretax Income | -9.24 | -3.16 | -10.72 | -25.01 | -42.06 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -9.24 | -3.16 | -10.72 | -25.01 | -42.06 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -9.24 | -3.16 | -10.72 | -25.01 | -42.06 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 152.31 | 158.00 | 153.20 | 147.11 | 119.72 |
Diluted EPS Before Non-Recurring Items | -0.06 | -0.02 | -0.07 | -0.17 | -0.35 |
Diluted Net EPS (GAAP) | -0.06 | -0.02 | -0.01 | -0.17 | -0.35 |